1. Introduction {#sec1-biomolecules-09-00157}
===============

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by the impaired immune tolerance of the immune system and the massive production of autoantibody, and eventually leads to a variety of tissues' and organs' functions being damaged, such as skin, blood vessels, kidney, etc \[[@B1-biomolecules-09-00157],[@B2-biomolecules-09-00157],[@B3-biomolecules-09-00157],[@B4-biomolecules-09-00157]\]. It is more prevalent in women than men, and its diverse manifestations and disease heterogeneity pose great challenges to the physical and mental health of women of childbearing age. \[[@B2-biomolecules-09-00157],[@B5-biomolecules-09-00157],[@B6-biomolecules-09-00157]\]. Although significant advances have been made in the current studies of SLE, the etiology and pathogenesis of the disease remain unclear, and generally believe to be the result of the interaction of environmental, genetic and immune factors \[[@B7-biomolecules-09-00157],[@B8-biomolecules-09-00157],[@B9-biomolecules-09-00157],[@B10-biomolecules-09-00157],[@B11-biomolecules-09-00157]\].

Currently, the imbalance between Treg cells and Th17 cells is considered to be an essential immunopathogenesis of multiple autoimmune diseases \[[@B12-biomolecules-09-00157],[@B13-biomolecules-09-00157],[@B14-biomolecules-09-00157],[@B15-biomolecules-09-00157],[@B16-biomolecules-09-00157],[@B17-biomolecules-09-00157],[@B18-biomolecules-09-00157]\]. Interleukin 35 (IL-35), the latest identified cytokine of interleukins 12 (IL-12) family, is consisted of two subunits (p35 and EBI3) \[[@B19-biomolecules-09-00157],[@B20-biomolecules-09-00157],[@B21-biomolecules-09-00157]\] and secreted by Treg cells \[[@B22-biomolecules-09-00157],[@B23-biomolecules-09-00157]\] and activated B cells \[[@B21-biomolecules-09-00157],[@B24-biomolecules-09-00157]\], etc. Studies revealed that IL-35 facilitates the differentiation and optimal immunosuppression of Treg cells \[[@B22-biomolecules-09-00157],[@B23-biomolecules-09-00157]\], and restrains the propagation and function of Th17 cells \[[@B25-biomolecules-09-00157],[@B26-biomolecules-09-00157],[@B27-biomolecules-09-00157]\]; the levels of IL-35 and IL-35 mRNA are significantly elevated in SLE patients \[[@B28-biomolecules-09-00157]\], and IL-35 can significantly relieve lupus flare and lupus nephritis, and reduce the plasma levels of proinflammatory cytokines (IFN-γ, TNF-α, IL-6 and IL-17A) and elevate the plasma levels of anti-inflammatory cytokines (IL-10 and IL-2) in MRL(Murphy Roths Large)/LPR mice \[[@B28-biomolecules-09-00157]\]. These findings suggest that IL-35 exerts crucial roles in the pathogenesis and development of SLE.

The encoding gene of p35 subunit, *IL-12A*, is located on chromosome 3q25.33, and several *IL-12A* polymorphisms were associated with the susceptibilities to primary biliary cirrhosis (PBC), Graves' disease and Alzheimer's disease \[[@B29-biomolecules-09-00157],[@B30-biomolecules-09-00157],[@B31-biomolecules-09-00157]\]; *EBI3*, the encoding gene of another subunit, EBI3, is located on chromosome 19q13.3, and the polymorphisms of *EBI3* rs428253, rs4740 and rs4905 were associated with the decreased risk of developing ulcerative colitis (UC) \[[@B32-biomolecules-09-00157]\]. Considering there is no evidence about the effects of IL-35 gene polymorphisms on SLE, in this case-control study we explored the associations between IL-35 gene polymorphisms and the susceptibility, main clinical manifestations, plasma IL-35 levels of SLE patients in a Chinese Han population, respectively.

2. Materials and Methods {#sec2-biomolecules-09-00157}
========================

2.1. Subjects {#sec2dot1-biomolecules-09-00157}
-------------

All the participants included in our study were of Chinese Han ancestry. A total of 490 SLE patients were recruited in our study from Department of Rheumatism and Immunity, the First Affiliated Hospital of Anhui Medical University and Department of Rheumatology and Immunology, Anhui Provincial Hospital, all the SLE patients met the criteria for the classification of SLE (American College of Rheumatology, 1997), and renal disorder of SLE was defined if any one of following definitions was satisfied: (a) Persistent proteinuria \> 0.5 g/d or \> 3+ if quantitation not performed; (b) Cellular casts: may be red blood cell, hemoglobin, granular, tubular, or mixed \[[@B33-biomolecules-09-00157]\]. 489 healthy controls were selected from the Health Examination Center, the First Affiliated Hospital of Anhui Medical University, all the healthy controls eligible to the inclusion criteria (a. do not meet any of the criteria for SLE classification, b. self and immediate relatives have no previous history of autoimmune diseases, c. match with SLE patients by age and gender). The informed consent was obtained from all the participants, and demographic profiles and clinical characteristics were collected from the participants. This study was approved by the Medical Ethics Committee of Anhui Medical University.

2.2. SNP Selection, Genotyping and Enzyme-Linked Immunosorbent Assay (ELISA) {#sec2dot2-biomolecules-09-00157}
----------------------------------------------------------------------------

The single nucleotide polymorphisms (SNPs) of IL-35 encoding gene, *IL-12A* and *EBI3*, were selected from HapMap database of Han Chinese population (CHB) in Beijing (HapMap Data Rel 24/phaseII Nov08, on NCBI B36 assembly, dbSNP b126) with minor allele frequency (MAF) ≥ 0.05. The pair-wise linkage disequilibrium (LD) between SNPs with r^2^ threshold of 0.8 was calculated by Haploview software (<http://www.broad.mit.edu/haploview/haploview>) \[[@B34-biomolecules-09-00157]\]. Eventually, seven tag SNPs were included in our study, including rs2227314, rs2243115, rs2243123, rs2243131 in *IL-12A* gene, and s428253, rs4740, rs9807813 in *EBI3* gene, the observed genotype frequencies of all genotyped SNPs were consistent with that of expected ones in healthy controls (all *p* \> 0.05) ([Table 1](#biomolecules-09-00157-t001){ref-type="table"}), and further genotyped by high-throughput SNPscan^TM^ genotyping assays (Genesky Biotechnologies Inc., Shanghai, China). Plasma IL-35 levels were assessed by Human IL-35 ELISA kits according to the manufacturer's instruction (R & D Systems, Inc. Minneapolis, MN, USA).

2.3. Statistical Analysis {#sec2dot3-biomolecules-09-00157}
-------------------------

Statistical analysis was performed by the Statistical Package for the Social Science (SPSS) version 23.0 for Windows. Shapiro-Wilk test was implemented for testing the normality of data, continuous data was described as mean ± SD for normally distributed data or median (interquartile range, IQR) for non-normally distributed data, and categorical data was presented as frequencies and percentages. The difference of continuous data was evaluated by *t*-test, F-test or Mann-Whitney U test, and that of categorical data was fulfilled by chi-square test or Fisher exact test. Hardy-Weinberg equilibrium (HWE) was tested to compare the frequencies of observed genotype to that of expected ones \[[@B35-biomolecules-09-00157]\], and haplotype analyses were completed using online platform SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>) \[[@B36-biomolecules-09-00157]\]. A two-sided *p* value less than 0.05 was considered as statistically significant.

3. Results {#sec3-biomolecules-09-00157}
==========

3.1. Demographic Characteristics, Clinical Features of Subjects {#sec3dot1-biomolecules-09-00157}
---------------------------------------------------------------

The demographic characteristics of all participants are presented in [Table 2](#biomolecules-09-00157-t002){ref-type="table"}, there were no significant differences in age and gender between SLE patients and healthy controls, respectively (*t* = 1.324, *p* = 0.186; χ^2^ = 0.096, *p* = 0.757). The clinical characteristics of SLE patients are illustrated in [Table 2](#biomolecules-09-00157-t002){ref-type="table"}, the major clinical features of SLE patients were butterfly rash (45.5%), arthritis (49.2%), hematological disorder (68.0%) and immunological disorder (73.3%).

3.2. Association of IL-35 Gene Polymorphisms with Risk of SLE {#sec3dot2-biomolecules-09-00157}
-------------------------------------------------------------

The allele frequencies and genotype frequencies of seven genotyped SNPs in SLE patients and healthy controls were presented in [Table 3](#biomolecules-09-00157-t003){ref-type="table"}, there were no significant differences in allele frequencies and genotype frequencies between SLE patients and healthy controls in all seven genotyped SNPs (rs2227314, rs2243115, rs2243123, rs2243131, rs428253, rs4740 and 9807813, all *p* \> 0.05). Furthermore, we explored the IL-35 gene polymorphisms with risk of SLE under dominant, recessive and additive model, and there were also no significant differences in IL-35 gene polymorphisms between SLE patients and healthy controls in all seven genotyped SNPs (all *p* \> 0.05) ([Table 3](#biomolecules-09-00157-t003){ref-type="table"}).

3.3. Association of IL-35 Gene Polymorphisms with the Clinical Features of SLE Patients {#sec3dot3-biomolecules-09-00157}
---------------------------------------------------------------------------------------

The associations between allele frequencies and genotype frequencies of seven genotyped SNPs and main clinical features of SLE patients were detailed in [Supplementary Tables (Tables S1 to S7)](#app1-biomolecules-09-00157){ref-type="app"}. There were significant differences in both genotype frequency and allele frequency of rs4740 between SLE patients with renal disorder and those without (χ^2^ =13.759, *p* = 0.001; χ^2^ = 11.804, *p* = 0.001); and there was a significant difference in genotype frequency of rs4740 between SLE patients with hematological disorder and those without (χ^2^ = 6.683, *p* = 0.036). However, there were no significant associations between genotype frequencies and allele frequencies of the other six SNPs (rs2227314, rs2243115, rs2243123, rs2243131, rs428253 and rs9807813) and the clinical features of SLE patients.

3.4. Association of Plasma IL-35 Levels with IL-35 Genotypes in SLE Patients {#sec3dot4-biomolecules-09-00157}
----------------------------------------------------------------------------

We randomly selected 76 plasma samples from 490 SLE patients and assessed their plasma IL-35 levels, the results revealed that there are no significant differences of plasma IL-35 levels in different IL-35 genotypes of each SNP, respectively ([Table 4](#biomolecules-09-00157-t004){ref-type="table"}).

3.5. Haplotype Analyses {#sec3dot5-biomolecules-09-00157}
-----------------------

Five main haplotypes (GGTA, GTTA, TTCA, TTTA and TTC) were constructed for rs2227314, rs2243115, rs2243123 and rs2243131 in *IL-12A* locus, and five main haplotypes (CAC, CGC, GAC, GAT and GGC) were constructed for rs428253, rs4740 and rs9807813 in *EBI3* locus. There were no significant differences in the frequency of each constructed haplotype in SLE patients and healthy controls ([Table 5](#biomolecules-09-00157-t005){ref-type="table"} and [Table 6](#biomolecules-09-00157-t006){ref-type="table"}).

4. Discussion {#sec4-biomolecules-09-00157}
=============

The disturbances in balance between Treg cells and Th17 cells have been considered as a new paradigm for pathogenesis of autoimmune diseases \[[@B3-biomolecules-09-00157],[@B18-biomolecules-09-00157],[@B37-biomolecules-09-00157]\]. IL-35 as a newly identified cytokine of IL-12 family exerts an indispensable role in the balance of Treg cells and Th17 cells \[[@B4-biomolecules-09-00157],[@B38-biomolecules-09-00157]\]. IL-35 abnormally elevated in SLE patients \[[@B39-biomolecules-09-00157]\], and significantly alleviated lupus flare, lupus nephritis and plasma levels of proinflammatory cytokines in MRL/lpr mice \[[@B28-biomolecules-09-00157]\]; there was an inverse correlation between serum IL-35 levels and disease activity in rheumatoid arthritis (RA) patients \[[@B40-biomolecules-09-00157]\], and IL-35 significantly relieved the synovial hypertrophy and bone destruction of RA model \[[@B41-biomolecules-09-00157]\]; serum IL-35 were significantly over-expressed in systemic sclerosis (SSc) patients \[[@B42-biomolecules-09-00157]\], and the frequency of Treg cells, the major source of IL-35, was associated with clinical phenotype and progression of SSc patients \[[@B43-biomolecules-09-00157]\]; IL-35 levels significantly reduced in inflammatory bowel diseases (IBD) patients and idiopathic thrombocytopenic purpura (ITP) patients \[[@B44-biomolecules-09-00157],[@B45-biomolecules-09-00157]\], exhibited a negative association with disease activity of IBD patients and a positive association with platelet counts in active ITP patients \[[@B44-biomolecules-09-00157],[@B45-biomolecules-09-00157]\]. All of this evidence implies that IL-35 is involved in the pathogenesis and progression of autoimmune diseases.

Several studies have explored the relations between the gene single nucleotide polymorphisms of interleukin 35 encoding genes (*IL-12A* and *EBI3*) and susceptibility to autoimmune diseases: genome-wide association analysis revealed that genetic variants of rs6441286, rs574808 in *IL-12A* locus were significantly associated with the PBC in North American white subjects \[[@B29-biomolecules-09-00157]\]; Guo et al. \[[@B30-biomolecules-09-00157]\] reported that the high frequency of allele A of *IL-12A* rs568408 related to the high Graves' disease risk in two Chinese cohort ; *IL-12A* rs568408 was significantly associated with the risk of late-onset Alzheimer's disease (LOAD), *IL-12A* rs2243115 elevated LOAD risk only in Apolipoprotein E, type ϵ4 allele carriers and genotype frequencies of *IL-12A* rs568408 had no significant associations with the risk of RA in Han Chinese populations \[[@B31-biomolecules-09-00157],[@B46-biomolecules-09-00157]\]; there were significant relations between *EBI3* rs428253 and protective effects against allergic rhinitis in Chinese subjects \[[@B47-biomolecules-09-00157]\]; rs428253, rs4740 and rs4905 in *EBI3* locus significantly correlated with the decreased UC risk in the Mexican population \[[@B32-biomolecules-09-00157]\].

In this study, we explored the associations between IL-35 gene single nucleotide polymorphisms with genetic susceptibility to SLE in a Chinese Han population. There were significant associations observed between the polymorphisms of rs4740 and the occurrence of renal disorder and hematological disorder in SLE patients, respectively, which echoed previous studies that rs4740 polymorphism exhibits protective effects on UC and pulmonary tuberculosis in Mexican and Chinese populations, respectively \[[@B32-biomolecules-09-00157],[@B48-biomolecules-09-00157]\]. Lupus nephritis, as one of the most devastating complications of SLE, predicts poor long-term outcomes with more than four-fold increase in mortality \[[@B49-biomolecules-09-00157]\]. In US, at the time of diagnosis around 35% SLE patients have clinical evidence of nephritis, within a decade of the illness estimated total of 50--60% patients develop nephritis \[[@B50-biomolecules-09-00157]\]. In the present study, the prevalence of renal disorder in SLE patients was 37.6% with median disease duration of 4.06 years. Previous study has suggested that serum IL-35 could be served as a potential biomarker of renal involvement in SLE patients; the serum levels of IL-35 were significantly lower in nephritis patients with higher levels of serum creatinine, blood urea nitrogen and blood uric acid \[[@B51-biomolecules-09-00157]\]. Our result adds novel evidence in elucidating the genetic underpinnings driving nephritis among SLE patients. However, there were no significant differences in both genotype frequencies and allele frequencies of all seven genotyped SNPs (rs2227314, rs2243115, rs2243123, rs2243131, rs428253, rs4740 and rs9807813) between SLE patients and healthy controls, and no significant associations between the polymorphisms of other genotyped SNPs (rs2227314, rs2243115, rs2243123, rs2243131, rs428253 and rs9807813) and the occurrence of main clinical manifestations in SLE patients. Posadas-Sánchez et al. \[[@B52-biomolecules-09-00157]\] illustrated that in healthy controls, IL-35 serum levels are significant different among different genotypes of rs4740 and rs4905, respectively. In this study, ELISA results demonstrated that plasma IL-35 levels have no significant association with genotype polymorphisms of all genotyped SNPs.

As far as we know, this is the first study explored about the associations between IL-35 gene single nucleotide polymorphisms and the genetic susceptibility to autoimmune diseases, in which IL-35 encoding genes, *IL-12A* and *EBI3*, were analyzed together. However, one limitation of our study should be considered, i.e., there was no information about the medication taking history of SLE patients and some of the SLE patients may have been treated with steroids or immunosuppressive agents, which potentially concealed the actual associations between plasma IL-35 levels and IL-35 gene single nucleotide polymorphisms, so further studies with known medication history of participants are needed to verify the results.

5. Conclusions {#sec5-biomolecules-09-00157}
==============

In conclusion, there is a significant association between the polymorphism of rs4740 and the occurrence of certain clinical manifestations in SLE patients, providing new clues for the prevention, diagnosis and treatment of SLE.

The following are available online at <https://www.mdpi.com/2218-273X/9/4/157/s1>, Supplementary Tables S1--S7.
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biomolecules-09-00157-t001_Table 1

###### 

SNPs genotyped in *IL-12A* and *EBI3* genes.

  Gene       SNP ID      Chr   Chr Position   Allele   mRNA          Region        *p* Value for HWE Test
  ---------- ----------- ----- -------------- -------- ------------- ------------- ------------------------
  *IL-12A*   rs2227314   3     159712054      G/T      NM_000882.3   Intron 6      0.902
  *IL-12A*   rs2243115   3     159706280      G/T      NM_000882.3   5′ Flanking   0.908
  *IL-12A*   rs2243123   3     159709651      C/T      NM_000882.3   Intron 2      0.891
  *IL-12A*   rs2243131   3     159712058      A/C      NM_000882.3   Intron 6      0.954
  *EBI3*     rs428253    19    4229913        C/G      NM_005755.2   Intron 1      0.262
  *EBI3*     rs4740      19    4236996        A/G      NM_005755.2   Exon 5        0.887
  *EBI3*     rs9807813   19    4232415        C/T      NM_005755.2   Intron 2      0.322

Chr, Chromosome; HWE, Hardy-Weinberg equilibrium.

biomolecules-09-00157-t002_Table 2

###### 

Demographic characteristics and clinical features of participants.

  Variable                        SLE Patients (n = 490)     Healthy Controls (n = 489)   *t/χ^2^*     *p* Value
  ------------------------------- -------------------------- ---------------------------- ------------ -----------
  Age (years)                     37.57 ± 11.49              38.53 ± 11.31                1.324 \*     0.186
  Gender, n (%)                                                                                        
  Male                            56 (11.4)                  59 (12.1)                    0.096 \*\*   0.757
  Female                          434 (88.6)                 430 (88.0)                                
  Disease duration, years         4.06 (1.05--8.90) \*\*\*                                             
  Butterfly rash, n (%)           223 (45.5)                                                           
  Discoid rash, n (%)             93 (19.0)                                                            
  Photosensitivity, n (%)         190 (38.8)                                                           
  Oral ulcers, n (%)              118 (24.1)                                                           
  Arthritis, n (%)                241 (49.2)                                                           
  Pleurisy, n (%)                 45 (9.2)                                                             
  Renal disorder, n (%)           184 (37.6)                                                           
  Neurological disorder, n (%)    21 (4.3)                                                             
  Hematological disorder, n (%)   333 (68.0)                                                           
  Immunological disorder, n (%)   359 (73.3)                                                           

\* *t*-test; \*\* χ^2^ test; \*\*\* median (interquartile range).

biomolecules-09-00157-t003_Table 3

###### 

Genotype and allele frequencies of genotyped SNPs in SLE patients and healthy controls.

  SNPs ID     Variable          Genotypes   SLE   Control   *χ^2^*   *p* Value    *OR*    95% *CI*
  ----------- ----------------- ----------- ----- --------- -------- ------------ ------- --------------
  rs2227314   Genotypes         GG          266   264       0.020    0.990                
                                TG          187   187                                     
                                TT          37    38                                      
              Allele            G           719   715       0.017    0.897        1.013   0.830--1.238
                                T           261   263                                     
              Dominant model    GG          266   264       0.009    0.925        1.012   0.787--1.301
                                TT + TG     224   225                                     
              Recessive model   GG + TG     453   451       0.017    0.897        1.032   0.644--1.652
                                TT          37    38                                      
              Additive model    GG          266   264       0.019    0.890        1.035   0.638--1.678
                                TT          37    38                                      
  rs2243115   Genotypes         TT          445   444                1.000 \*             
                                TG          44    45                                      
                                GG          1     0                                       
              Allele            T           934   933       0.009    0.922        0.979   0.643--1.492
                                G           46    45                                      
              Dominant model    TT          445   444       0.000    0.992        1.002   0.650--1.546
                                GG + TG     45    45                                      
              Recessive model   TT + TG     489   489       0.000    1.000 \*\*           
                                GG          1     0                                       
              Additive model    TT          445   444       0.000    1.000 \*\*           
                                GG          1     0                                       
  rs2243123   Genotypes         TT          422   416                0.250 \*\*           
                                TC          62    71                                      
                                CC          6     2                                       
              Allele            T           906   903       0.010    0.922        1.017   0.728--1.420
                                C           74    75                                      
              Dominant model    TT          422   416       0.219    0.640        1.089   0.762--1.556
                                CC + TC     68    73                                      
              Recessive model   TT + TC     484   487       1.128    0.288 \*\*   0.331   0.067--1.649
                                CC          6     2                                       
              Additive model    TT          422   416       1.065    0.302 \*\*   0.338   0.068--1.685
                                CC          6     2                                       
  rs2243131   Genotypes         AA          385   370       1.218    0.544                
                                AC          97    109                                     
                                CC          8     10                                      
              Allele            A           867   849       1.245    0.265        1.166   0.890--1.527
                                C           113   129                                     
              Dominant model    AA          385   370       1.172    0.279        1.179   0.875--1.590
                                CC + AC     105   119                                     
              Recessive model   AA + AC     482   479       0.231    0.631        1.258   0.492--3.214
                                CC          8     10                                      
              Additive model    AA          385   370       0.302    0.583        1.301   0.508--3.332
                                CC          8     10                                      
  rs428253    Genotypes         GG          321   321       0.755    0.686                
                                GC          156   159                                     
                                CC          13    9                                       
              Allele            G           798   801       0.073    0.787        0.969   0.771--1.218
                                C           182   177                                     
              Dominant model    GG          321   321       0.002    0.965        0.994   0.764--1.294
                                CC + GC     169   168                                     
              Recessive model   GG + GC     477   480       0.736    0.391        0.688   0.291--1.625
                                CC          13    9                                       
              Additive model    GG          321   321       0.703    0.402        0.692   0.292--1.642
                                CC          13    9                                       
  rs4740      Genotypes         GG          172   161       0.545    0.762                
                                GA          224   233                                     
                                AA          94    95                                      
              Allele            G           568   555       0.293    0.588        1.051   0.878--1.257
                                A           412   423                                     
              Dominant model    GG          172   161       0.517    0.472        1.102   0.846--1.436
                                AA + GA     318   328                                     
              Recessive model   GG + GA     396   394       0.009    0.923        1.016   0.740--1.395
                                AA          94    95                                      
              Additive model    GG          172   161       0.177    0.674        1.080   0.755--1.543
                                AA          94    95                                      
  rs9807813   Genotypes         CC          321   308       4.740    0.093                
                                TC          147   169                                     
                                TT          22    12                                      
              Allele            C           789   785       0.019    0.892        1.016   0.813--1.269
                                T           191   193                                     
              Dominant model    CC          321   308       0.679    0.410        1.116   0.859--1.450
                                TT + TC     169   181                                     
              Recessive model   CC + TC     468   477       3.026    0.082        0.535   0.262--1.094
                                TT          22    12                                      
              Additive model    CC          321   308       2.415    0.120        0.568   0.277--1.169
                                TT          22    12                                      

\* Fisher's Exact Test; \*\* Continuity Correction; OR, odds ratio; CI, confidence interval.
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###### 

Associations of plasma IL-35 levels with IL-35 genotypes in SLE patients.

  SNP ID      Genotypes   *n*   IL-35 Level (pg/mL)   *p* Value            
  ----------- ----------- ----- --------------------- ----------- -------- -------
  rs2227314   GG          46    61.51                 55.7        72.96    0.538
              TG          25    59.51                 52.99       68.57    
              TT          5     64.58                 55.4        68.24    
  rs2243115   TT          73    61.66                 55.07       71.55    0.416
              TG          3     59.51                 56.11       59.79    
  rs2243123   TT          70    54.23                 60.05       71.51    0.315
              TC          5     63.12                 68.98       83.05    
              CC          1     61.61                 \-          \-       
  rs2243131   AA          65    61.61                 55.07       72.08    0.409
              AC          10    57.88                 48.19       66.74    
              CC          1     67.51                 \-          \-       
  rs428253    GG          45    62.92                 55.09       72.08    0.746
              GC          30    59.23                 54.14       70.32    
              CC          1     63.72                 \-          \-       
  rs4740      GG          29    60.88                 54.12       70.70    0.816
              GA          29    58.71                 53.7        72.98    
              AA          18    63.52                 57.87       72.62    
  rs9807813   CC          51    61.61                 54.99       71.46    0.666
              TC          21    59.51                 54.36       70.78    
              TT          4     69.33                 44.32       212.58   

*M*, median; *P25*, percentile 25th, *P75*, percentile 75th, representing the interquartile range.

biomolecules-09-00157-t005_Table 5

###### 

Haplotype analysis results among four SNPs in *IL-12A* locus.

  Haplotypes   SLE      Control   *χ^2^*   *p* Value   *OR*    95% *CI*           
  ------------ -------- --------- -------- ----------- ------- ---------- ------- --------------
  GGTA         32.34    3.3%      28.92    3.0%        0.188   0.665      1.119   0.672--1.864
  GTTA         681.72   69.6%     686.08   70.2%       0.095   0.758      0.969   0.795--1.182
  TTCA         63.76    6.5%      62.4     6.4%        0.012   0.912      1.021   0.711--1.465
  TTTA         80.07    8.2%      67.12    6.9%        1.200   0.273      1.207   0.861--1.692
  TTTC         99.68    10.2%     110.64   11.3%       0.672   0.412      0.887   0.666--1.182

Total *χ^2^* = 1. 927, *df* = 4, *P* = 0.749. All the haplotypes with a frequency \<0.03 were ignored in the analysis. OR, odds ratio; CI, confidence interval.
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###### 

Haplotype analysis results among three SNPs in *EBI3* locus.

  Haplotypes   SLE      Control   *χ^2^*   *p* Value   *OR*    95% *CI*           
  ------------ -------- --------- -------- ----------- ------- ---------- ------- --------------
  CAC          119.38   12.2%     103.00   10.5%       1.433   0.231      1.186   0.897--1.570
  CGC          57.14    5.8%      71.86    7.3%        1.744   0.187      0.785   0.548--1.125
  GAC          109.22   11.1%     132.13   13.5%       2.388   0.122      0.808   0.616--1.059
  GAT          178.17   18.2%     185.74   19.0%       0.161   0.688      0.954   0.760--1.199
  GGC          503.26   51.4%     478.01   48.9%       1.511   0.219      1.118   0.936--1.336

Total *χ^2^* = 5.863, *df* = 4, *p* = 0.230. All the haplotypes with a frequency \< 0.03 were ignored in the analysis. OR, odds ratio; CI, confidence interval.
